It’s an intricate, time-intensive process getting a grant from the National Institutes of Health, which is part of the reason researchers are concerned about the current murkiness surrounding federal funding. One canceled meeting, for instance, could set a project back months — or perhaps cripple it completely.
Applicants must navigate a multistep process before receiving NIH-funded grants, explained Craig Kaplan, a professor in Pitt’s biological sciences department. His lab receives financial support from a five-year NIH grant.
NIH review panels, also called "Scientific Review Groups" or study sections, conduct the initial peer review of grant applications by evaluating their scientific merit based on criteria such as significance, innovation and approach. Mr. Kaplan is a member of one of these review panels — Molecular Genetics (MG). The MG study section is one of nine such panels under the umbrella of the Molecular Genetics and Genomics Review Branch.
If a review panel finds merit in a grant request, they’ll forward it to the next stage: the NIH councils, composed of scientific experts and public representatives. These councils provide a second-level review to assess the applications' relevance to the institute's mission and make funding recommendations. They base these recommendations on the initial peer review scores and summary statements. Each of the 27 institutes and centers that make up the NIH has its own councils, branches and panels.
Essentially, panels evaluate the science while councils consider the broader impact and funding priorities within the institute. Both panels and councils meet three times per year, but not necessarily at the same time or even on similar schedules.
The process to receive grant funding is quite lengthy. If one part of the process is disrupted, it’s not a simple matter of a slight delay.
Read More
If a council is canceled, the next one won’t happen for approximately four months. Each council follows its own timeline, but meetings are generally held in February, May and September, Mr. Kaplan said. Additionally, council members travel to the meetings from all over the world, so advance planning and coordination are essential.
A canceled council or study session could quickly result in a backlog of proposals, which would then have to be dealt with at the next scheduled gathering months later, or projects could simply fall apart because researchers will have found other jobs, perhaps on the other side of the world, training will have ceased, labs could close and programs eliminated, Mr. Kaplan said.
And getting an NIH grant proposal ready for submission is no easy task, said Carnegie Mellon University graduate and former Marine Corps officer Brad Holden of Resilient Lifesciences, a North Shore startup that is focused on developing a Narcan patch. The small company, which Mr. Holden co-founded with Yale-trained software engineer Charlie Proctor, is operating partly thanks to a $3.4 million NIH grant.
“The week I submitted the grant, I stayed up three days in a row, just writing continuously,” Mr. Holden said. The “grueling” application numbered about 200 pages, all told.
“The acceptance rate for these is in the 10-20% range,” he said, adding that each proposal receives abundant scrutiny from top experts in the field.
“You look at the folks that are on these review panels, they're incredibly accomplished people. They're very, very intelligent,” Mr. Holden said. “The amount of scrutiny and diligence that goes into funding” NIH grants is as stringent as possible. “I can't think of a process that would lead to dramatically better results than what they're doing right now.”





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.